Clinical Trials Browser

OTHER_GOV × Clinical Trials, Phase II as Topic × Clear all

NCT05429905 2023-03-09

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma